Table 1.
Characteristics of 401 patients with acute GVHD grades II–IV after reduced-intensity allogeneic HCT.
| Age at HCT, years | |
| Median (range) | 55 (<1–75) |
|
| |
| Gender | |
| Male | 254 (63%) |
| Female | 147 (37%) |
|
| |
| Donor | |
| Related donor | 164 (41%) |
| Unrelated donor | 237 (59%) |
| HLA-matched | 173 |
| HLA-mismatched | 64 |
|
| |
| Transplant indication | |
| Acute myeloid leukemia | 104 |
| Non-Hodgkin lymphoma | 77 |
| Multiple myeloma | 56 |
| Chronic lymphocytic leukemia | 39 |
| Myelodysplastic syndrome | 25 |
| Primary ID/marrow failure | 25 |
| Acute lymphoblastic leukemia | 24 |
| Hodgkin lymphoma | 23 |
| Chronic myelogenous leukemia | 11 |
| Aplastic anemia | 7 |
| Solid tumor | 6 |
| Myeloproliferative disorder | 4 |
|
| |
| Conditioning regimen | |
| 2 Gy TBI | 51 |
| 2 Gy TBI + fludarabine 90 mg/m2 | 320 |
| 3 Gy TBI + fludarabine 90 mg/m2 | 14 |
| 4 Gy TBI + fludarabine 90 mg/m2 | 7 |
| CY 200 mg/kg + hATG 90 mg/kg | 8 |
| No conditioning | 1 |
|
| |
| Stem cell source | |
| G-PBMC | 370 (92%) |
| Bone marrow | 31 (8%) |
|
| |
| CD34+ cell dose, cells/kg | |
| Median | 7.82 × 106 |
|
| |
| Median time to acute GVHD onset | 35 days |
|
| |
| Peak acute GVHD grade | |
| II | 325 (81%) |
| III–IV | 76 (19%) |
Abbreviations: HCT, hematopoietic cell transplantation; HLA, human leukocyte antigen; ID, immunodeficiency; TBI, total body irradiation; CY, cyclophosphamide; hATG, horse antithymocyte globulin; G-PBMC, granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells; acute GVHD, acute graft-vs.-host disease.